Companies › Spectrum Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eflapegrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 2 | Solid Tumors | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04570423 | Eflapegrastim | Phase 2 | Solid Tumors | Oncology | Oct 2027 |
Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Savara Qilu Pharmaceutical Kexing Biopharm Yaqrit
Buzzard Pharmaceuticals Cellvax Therapeutics Newish Technology (Beijing) BrainChild Bio TVAX Biomedical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.